ZURA BIO LTD (ZURA) Fundamental Analysis & Valuation

NASDAQ:ZURA • KYG9TY5A1016

7.04 USD
+0.07 (+1%)
At close: Mar 9, 2026
7.1 USD
+0.06 (+0.85%)
After Hours: 3/9/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ZURA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZURA. ZURA was compared to 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZURA as it has an excellent financial health rating, but there are worries on the profitability. ZURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. ZURA Profitability Analysis

1.1 Basic Checks

  • ZURA had negative earnings in the past year.
  • In the past year ZURA has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ZURA reported negative net income in multiple years.
  • ZURA had a negative operating cash flow in each of the past 5 years.
ZURA Yearly Net Income VS EBIT VS OCF VS FCFZURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • ZURA has a Return On Assets (-43.44%) which is in line with its industry peers.
  • The Return On Equity of ZURA (-57.76%) is better than 60.50% of its industry peers.
Industry RankSector Rank
ROA -43.44%
ROE -57.76%
ROIC N/A
ROA(3y)-30.48%
ROA(5y)N/A
ROE(3y)-48.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZURA Yearly ROA, ROE, ROICZURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

  • ZURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZURA Yearly Profit, Operating, Gross MarginsZURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ZURA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ZURA has more shares outstanding
  • ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZURA Yearly Shares OutstandingZURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ZURA Yearly Total Debt VS Total AssetsZURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 7.40 indicates that ZURA is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.40, ZURA is doing good in the industry, outperforming 77.46% of the companies in the same industry.
  • ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.4
ROIC/WACCN/A
WACCN/A
ZURA Yearly LT Debt VS Equity VS FCFZURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • ZURA has a Current Ratio of 5.58. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
  • ZURA has a Current ratio (5.58) which is comparable to the rest of the industry.
  • ZURA has a Quick Ratio of 5.58. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
  • ZURA's Quick ratio of 5.58 is fine compared to the rest of the industry. ZURA outperforms 60.89% of its industry peers.
Industry RankSector Rank
Current Ratio 5.58
Quick Ratio 5.58
ZURA Yearly Current Assets VS Current LiabilitesZURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ZURA Growth Analysis

3.1 Past

  • The earnings per share for ZURA have decreased by -4.69% in the last year.
EPS 1Y (TTM)-4.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ZURA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -18.87% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.36%
EPS Next 2Y-18.21%
EPS Next 3Y-6.25%
EPS Next 5Y-18.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZURA Yearly Revenue VS EstimatesZURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
ZURA Yearly EPS VS EstimatesZURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. ZURA Valuation Analysis

4.1 Price/Earnings Ratio

  • ZURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZURA Price Earnings VS Forward Price EarningsZURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZURA Per share dataZURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • A cheap valuation may be justified as ZURA's earnings are expected to decrease with -6.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.21%
EPS Next 3Y-6.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZURA Dividend Analysis

5.1 Amount

  • ZURA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZURA Fundamentals: All Metrics, Ratios and Statistics

ZURA BIO LTD

NASDAQ:ZURA (3/9/2026, 8:00:03 PM)

After market: 7.1 +0.06 (+0.85%)

7.04

+0.07 (+1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)04-01
Inst Owners62.58%
Inst Owner ChangeN/A
Ins Owners5.66%
Ins Owner Change5.06%
Market Cap606.99M
Revenue(TTM)N/A
Net Income(TTM)-62.52M
Analysts87.14
Price Target16.17 (129.69%)
Short Float %7.33%
Short Ratio5.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.99%
Min EPS beat(2)-13.48%
Max EPS beat(2)11.5%
EPS beat(4)2
Avg EPS beat(4)4.34%
Min EPS beat(4)-17.47%
Max EPS beat(4)36.82%
EPS beat(8)4
Avg EPS beat(8)1.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.89%
PT rev (3m)-0.89%
EPS NQ rev (1m)2.45%
EPS NQ rev (3m)2.45%
EPS NY rev (1m)0.47%
EPS NY rev (3m)0.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.61
P/tB 5.61
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.44%
ROE -57.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.48%
ROA(5y)N/A
ROE(3y)-48.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 361.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.58
Quick Ratio 5.58
Altman-Z 7.4
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
EPS Next Y-39.36%
EPS Next 2Y-18.21%
EPS Next 3Y-6.25%
EPS Next 5Y-18.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-179.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-379.86%
OCF growth 3YN/A
OCF growth 5YN/A

ZURA BIO LTD / ZURA FAQ

Can you provide the ChartMill fundamental rating for ZURA BIO LTD?

ChartMill assigns a fundamental rating of 2 / 10 to ZURA.


What is the valuation status of ZURA BIO LTD (ZURA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZURA BIO LTD (ZURA). This can be considered as Overvalued.


Can you provide the profitability details for ZURA BIO LTD?

ZURA BIO LTD (ZURA) has a profitability rating of 1 / 10.


What is the financial health of ZURA BIO LTD (ZURA) stock?

The financial health rating of ZURA BIO LTD (ZURA) is 7 / 10.